title: Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.
authors.forename: V G
authors.initials: VG
authors.lastname: Oehler
authors.forename: J
authors.initials: J
authors.lastname: Qin
authors.forename: R
authors.initials: R
authors.lastname: Ramakrishnan
authors.forename: G
authors.initials: G
authors.lastname: Facer
authors.forename: S
authors.initials: S
authors.lastname: Ananthnarayan
authors.forename: C
authors.initials: C
authors.lastname: Cummings
authors.forename: M
authors.initials: M
authors.lastname: Deininger
authors.forename: N
authors.initials: N
authors.lastname: Shah
authors.forename: F
authors.initials: F
authors.lastname: McCormick
authors.forename: S
authors.initials: S
authors.lastname: Willis
authors.forename: A
authors.initials: A
authors.lastname: Daridon
authors.forename: M
authors.initials: M
authors.lastname: Unger
authors.forename: J P
authors.initials: JP
authors.lastname: Radich
mesh_terms: D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000235:genetics*; D046210:Microfluidic Analytical Techniques / Q000295:instrumentation; D036103:Nanotechnology / Q000295:instrumentation*; D017354:Point Mutation; D016133:Polymerase Chain Reaction / Q000379:methods* / Q000592:standards; D012680:Sensitivity and Specificity
chemical_list: D016044:Fusion Proteins, bcr-abl